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and glycoprotein IIb/IIIa inhibitors were used in 90 patients (62%). For
hemodynamic support, 141 patients (97%) received inotropic supportby cardiogenic shock in the contemporary era
of primary percutaneous coronary interventionTable 1
Baseline clinical characteristics, clinical presentation and angiographic ﬁndings.
N = 145
Mean age, years 63.1 ± 12.1
Male:female, n (%) 127:18 (88:12)
Ever smokers, n (%) 98 (68)
Diabetes, n (%) 50 (35)
Hyperlipidemia, n (%) 63 (43)
Hypertension, n (%) 84 (58)
Previous myocardial infarction, n (%) 15 (10.3)
Previous PCI, n (%) 13 (9.0)
Previous CABG, n (%) 3 (2.1)
LVEF (%) 34 ± 12
Presentation
Chest pain, n (%) 114 (79)
Out-of-hospital collapse, n (%) 17 (12)
Anterior STEMI, n (%) 74 (51)
Number of obstructed coronary arteries
1, n (%) 20 (14)
2, n (%) 47 (32)
3, n (%) 78 (54)
PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting;
LVEF = left ventricular ejection fraction; STEMI = ST-elevation myocardial infarction.Keywords:
Cardiogenic shock
Mortality
Primary percutaneous coronary
Intervention
Predictor
Primary percutaneous coronary intervention (PPCI) is currently the
preferred reperfusion therapy for patientswith ST-elevationmyocardial
infarction (STEMI). About 5–10% of all acute myocardial infarction
(AMI) cases are complicated by cardiogenic shock (CS) which is associ-
ated with a high in-hospital mortality rate [1–3]. The mortality beneﬁt
of earlymechanical revascularization has been demonstrated in the land-
mark SHOCK trial [4] which compared emergency revascularization (PCI
or coronary artery bypass grafting) versus a strategy of initialmedical sta-
bilization using ﬁbrinolysis and insertion of intra-aortic balloon pump
(IABP) inAMI patientswith CS. The SHOCK trial, however,was conducted
more than a decade ago and there is limited data [5,6] on the clinical out-
come of this group of patients in the contemporary era of PPCI.
We therefore sought to evaluate the survival rate and predictors of
in-hospitalmortality in our cohort of Asian patientswith AMI complicat-
ed by CS who underwent PPCI at our institution from January 2009 to
December 2010. Cardiogenic shock was deﬁned as a systolic blood
pressure (SBP) of b90 mm Hg for N30 min or the need for supportive
measures to maintain a SBP N90mmHg, associated with end-organ hy-
poperfusion. Clinical data was collected retrospectively on demographic
characteristics, presenting signs and symptoms, laboratory investiga-
tions, angiographic ﬁndings, hospital course and in-hospital mortality.
Our study conforms to the ethical guidelines of the 1975 Declaration of
Helsinki and was approved by the institution's research committee.
Table 1 shows the baseline clinical characteristics, clinical presenta-
tion and angiographic ﬁndings of our patients. The mean age at presen-
tation was 63.1 ± 12.1 years with male predominance (88%). The
majority of patients (51%) presented with anterior MI with 86% found
to havemulti-vessel disease on coronary angiography. Diabetesmellitus
was present in 50 patients (35%). The mean ejection fraction was
34 ± 12%. 17 patients (12%) presented with out-of-hospital collapse.
Table 2 shows the PCI procedural variables and in-hospital clinical
outcomes of our patients. The most common target vessel for PPCI was
the left anterior descending artery (44%) followed by the right coronary
artery (36%), left main artery (11%) and left circumﬂex artery (9%). The
majority of patients (65%) received bare metal stent implantation during
PPCIwithpost-procedural Thrombolysis inMyocardial Infarction (TIMI) 3
ﬂow achieved in 77% of patients. Themedian door-to-balloon (D2B) time
was 63 ± 30 min. Multi-vessel PCI was performed in 26 patients (18%)http://dx.doi.org/10.1016/j.ijchv.2014.04.001
2214-7632/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access articland 100 patients (69%) received intra-aortic balloon counterpulsation. 5
patients (3.4%) received extracorporeal membrane oxygenation for
refractory shock. The overall in-hospital mortality was 28% (40 patients).
106 patients (73%) developed severe heart failure (New York Heart Asso-
ciation Classes III to IV)with 74 patients requiringmechanical ventilation.
38 patients (26%) developed cardiac arrest during/after PPCI and 32
patients (22%) developed acute kidney injury (AKI; deﬁned as ≥50%
increase in serum creatinine in b48 h) during hospitalization.
Factors associated with in-hospital mortality by univariate analysis
were older age at presentation, history of cardiac arrest, occlusive left
main disease, post procedural TIMI ﬂow, severe heart failure and AKI.
By multi-variate analysis, independent predictors of in-hospital mortal-
ity were history of cardiac arrest (hazard ratio: 17.5, 95% CI: 4.7–65.2,
p = 0.001) and AKI (hazard ratio: 11.1, 95% CI: 2.7–45.5, p = 0.001).
Patients with AMI complicated by CS represent the sickest group of
patients in the AMI disease spectrum and posed a great challenge to
clinicians worldwide [7]. As mentioned previously, these patients have
a high in-hospital mortality rate, ranging from 40 to 74% [1–6]. Previous
studies (many performed in the thrombolytic era) including the SHOCK
trial/registry have shown that predictors of in-hospital mortality in-
clude advanced age, prior MI, left ventricular ejection fraction, severity
of mitral regurgitation, left main disease/saphenous vein graft as culprit
lesion, extent of coronary artery disease, etc. [8–10]. There is, however,
limiteddata [5,6] on the clinical outcomeof this groupof patients and its
predictors in the contemporary era of PPCI.
PPCI is currently the main reperfusion therapy for STEMI patients in
many parts of the world including Singapore. In our study, the overalle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 2
Percutaneous coronary intervention procedural variables and in-hospital clinical
outcomes.
N = 145
Culprit vessel
Left main, n (%) 16 (11)
LAD, n (%) 64 (44)
RCA, n (%) 52 (36)
LCx, n (%) 13 (9)
Multi-vessel PCI, n (%) 26 (18.0)
Median D2B time, min 63 ± 30
Bare metal stenting, n (%) 94 (65.0)
Glycoprotein IIb/IIIa inhibitors, n (%) 90 (62)
Inotropic support, n (%) 141 (97)
IABP, n (%) 100 (69)
ECMO, n (%) 5 (3.4)
Post PCI TIMI ﬂow
TIMI 2, n (%) 23 (15.9)
TIMI 3, n (%) 111 (77.0)
In-hospital clinical outcomes
All-cause mortality, n (%) 40 (28.0)
Heart failure (NYHA III–IV), n (%) 106 (73)
Cardiac arrest, n (%) 38 (26)
Acute kidney injury, n (%) 32 (22)
LAD = left anterior descending; RCA = right coronary artery; LCx = left circumﬂex;
PCI = percutaneous coronary intervention; D2B = door-to-balloon; IABP = intra-
aortic balloon pump; ECMO = extracorporeal membrane oxygenation; TIMI =
Thrombolysis in Myocardial Infarction; NYHA = New York Heart Association.
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were found to be associated with in-hospital mortality i.e. older age at
presentation, history of cardiac arrest, occlusive left main disease, post
procedural TIMI ﬂow, severe heart failure and AKI. Independent predic-
tors of in-hospital mortality identiﬁed in our study were history of
cardiac arrest and AKI.
55 patients (38%) in our study had a history of cardiac arrest (includ-
ing the 17 patients who presented with out-of-hospital collapse) of
which 31 patients succumbed. The most common type of cardiac arrest
(total number of episodes = 69) was ventricular ﬁbrillation/pulseless
ventricular tachycardia (45%) followed by pulseless electrical alternans
(35%) and asystole (20%).
The incidence of AKI in our study was 22% and 4 patients require
temporary hemodialysis. This is consistent with prior studies which
have shown that AKI affects approximately 20–30% of critically-ill
patients. The etiology of AKI in AMI patients with CS is likely to be
multi-factorial. Themanagement of AKI depends largely on identiﬁcation
and treatment of the underlying cause and also, avoidance of nephrotox-
ic substances.
Despite achieving a short median D2B time for PPCI, the in-hospital
mortality of our patients with AMI and CS remained relatively high.
Symptom onset to reperfusion time is an important determinant of
mortality in AMI patients, perhaps more so in patients with CS. This
parameter warrants further investigation in our group of patients. The
results of our study also showed that history of cardiac arrest and AKIwere independent predictors of in-hospital mortality. These two
“complications” are potentially preventable. Novel treatment options
are certainly needed to improve the adverse prognosis of AMI patients
with CS in the contemporary era of PPCI.References
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